case_images: PMC7186327_01
case_images: Changes in tumor or metastasis size by computed tomography (CT) imaging before and after initiation of checkpoint blockade immunotherapy. Representative imaging showing decrease in size of colon mass for patient #1 (A,B) and liver metastasis for patient #2 (C,D) and patient #3 (E,F).
case_images: fonc-10-00581-g0002.jpg
case_images: PMC7186327_03_fonc-10-00581-g0002.jpg
case_images: F2
case_images: Within 5 months, these symptoms progressed to urinary retention, and imaging revealed a 5.5 cm sigmoid mass with invasion into the bladder and metastatic liver lesions (Figure 2E). Following an uncomplicated postoperative recovery, he was started on dual checkpoint blockade, nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4), with a partial response of the liver metastases (Figure 2F).
case_images: PMC7186327_02
case_images: Changes in tumor or metastasis size by computed tomography (CT) imaging before and after initiation of checkpoint blockade immunotherapy. Representative imaging showing decrease in size of colon mass for patient #1 (A,B) and liver metastasis for patient #2 (C,D) and patient #3 (E,F).
case_images: fonc-10-00581-g0002.jpg
case_images: PMC7186327_03_fonc-10-00581-g0002.jpg
case_images: F2
case_images: Within 5 months, these symptoms progressed to urinary retention, and imaging revealed a 5.5 cm sigmoid mass with invasion into the bladder and metastatic liver lesions (Figure 2E). Following an uncomplicated postoperative recovery, he was started on dual checkpoint blockade, nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4), with a partial response of the liver metastases (Figure 2F).
case_images: PMC7186327_03
case_images: Changes in tumor or metastasis size by computed tomography (CT) imaging before and after initiation of checkpoint blockade immunotherapy. Representative imaging showing decrease in size of colon mass for patient #1 (A,B) and liver metastasis for patient #2 (C,D) and patient #3 (E,F).
case_images: fonc-10-00581-g0002.jpg
case_images: PMC7186327_03_fonc-10-00581-g0002.jpg
case_images: F2
case_images: Within 5 months, these symptoms progressed to urinary retention, and imaging revealed a 5.5 cm sigmoid mass with invasion into the bladder and metastatic liver lesions (Figure 2E). Following an uncomplicated postoperative recovery, he was started on dual checkpoint blockade, nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4), with a partial response of the liver metastases (Figure 2F).